Cargando…

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease

Chronic inflammation drives the development of atherosclerosis. Despite optimal treatment of classical cardiovascular risk factors, a substantial portion of the population has elevated inflammatory biomarkers and develops atherosclerosis-related complications, indicating that a residual inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bosmans, Laura A., Bosch, Lena, Kusters, Pascal J.H., Lutgens, Esther, Seijkens, Tom T.P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892683/ https://www.ncbi.nlm.nih.gov/pubmed/32222950 http://dx.doi.org/10.1007/s12265-020-09994-3

Ejemplares similares

The CD40–CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
por: Aarts, Suzanne A. B. M., et al.
Publicado: (2017)

Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis
por: Aarts, Suzanne ABM, et al.
Publicado: (2019)

CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease—The Pros and Cons for Cardioprotection
por: Daub, Steffen, et al.
Publicado: (2020)

Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease
por: Lacy, Michael, et al.
Publicado: (2021)

E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
por: Poels, Kikkie, et al.
Publicado: (2020)

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis
por: Seijkens, Tom T.P., et al.
Publicado: (2018)

Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease
por: Lutgens, Esther, et al.
Publicado: (2020)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

CD40–CD40L in Neurological Disease
por: Ots, Heather D., et al.
Publicado: (2022)

Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation
por: Aarts, Suzanne A. B. M., et al.
Publicado: (2017)

Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures
por: Pototskiy, Esther, et al.
Publicado: (2021)

Adipocytes control hematopoiesis and inflammation through CD40 signaling
por: Reiche, Myrthe E., et al.
Publicado: (2022)

CD40 in coronary artery disease: a matter of macrophages?
por: Jansen, Matthijs F., et al.
Publicado: (2016)

CD40-CD40L Interaction in Immunity Against Protozoan Infections
por: Chamekh, Mustapha
Publicado: (2007)

Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Author Correction: Downregulation of CD40L–CD40 attenuates seizure susceptibility and severity of seizures
por: Pototskiy, Esther, et al.
Publicado: (2021)

The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update
por: Senhaji, Nezha, et al.
Publicado: (2015)

CD40L membrane retention enhances the immunostimulatory effects of CD40 ligation
por: Elmetwali, Taha, et al.
Publicado: (2020)

CD40/CD40L expression and its prognostic value in cervical cancer
por: Grazia, G.A., et al.
Publicado: (2023)

CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease
por: Zhang, Shungang, et al.
Publicado: (2020)

Involvement of CD40-CD40L and ICOS-ICOSL in the development of chronic rhinosinusitis by targeting eosinophils
por: Zhou, Aina, et al.
Publicado: (2023)

Soluble CD40 Levels in Plasma Are Associated with Cardiovascular Disease and in Carotid Plaques with a Vulnerable Phenotype
por: Shami, Annelie, et al.
Publicado: (2021)

Expression of CD40 and CD40L in Gastric Cancer Tissue and Its Clinical Significance
por: Li, Rui, et al.
Publicado: (2009)

Expression of CD40, CD40L and IgM production in patients with ataxia-telangiectasia
por: Pereira, Camila Teles Machado, et al.
Publicado: (2015)

Multiple effects of CD40–CD40L axis in immunity against infection and cancer
por: Ara, Anjuman, et al.
Publicado: (2018)

RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse
por: Chen, Yizhi, et al.
Publicado: (2023)

Depletion of CD40 on CD11c(+) cells worsens the metabolic syndrome and ameliorates hepatic inflammation during NASH
por: Aarts, Suzanne, et al.
Publicado: (2019)

Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals
Publicado: (1995)

The CD40 rs1883832 Polymorphism Affects Sepsis Susceptibility and sCD40L Levels
por: Liu, Zuo-Liang, et al.
Publicado: (2018)

Multimeric forms of CD40 ligand (CD40L), 4-1BB ligand (4-1BBL), OX40 ligand (OX40L), CD27L/CD70, and other TNFSFs as tools for adoptive cell therapy
por: Kornbluth, Richard S
Publicado: (2013)

Deficiency of T cell CD40L has minor beneficial effects on obesity-induced metabolic dysfunction
por: Reiche, Myrthe E, et al.
Publicado: (2019)

Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets
por: Chen, Tso-Hsiao, et al.
Publicado: (2015)

Adipocytes in their (CD)40s
por: Bertola, Adeline, et al.
Publicado: (2023)

Evidence of CD40L/CD40 pathway involvement in experimental transfusion-related acute lung injury
por: Tariket, Sofiane, et al.
Publicado: (2019)

Causal associations between CD40/CD40L and aortic diseases: A mendelian randomization study
por: Cui, Xiao, et al.
Publicado: (2022)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

The Role of CD40/CD40 Ligand Interactions in Bone Marrow Granulopoiesis
por: Mavroudi, Irene, et al.
Publicado: (2011)

CD40/CD40 LIGAND INTERACTIONS IN IMMUNE RESPONSES AND PULMONARY IMMUNITY
por: KAWABE, TSUTOMU, et al.
Publicado: (2011)

Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile
por: Lutgens, Esther, et al.
Publicado: (2010)

CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells
por: Naito, Masayasu, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3obrb1q4ccat9qgfk5ebtabkkq